The present invention relates to the mannose-receptor selective lysinylated cationic amphiphile and a process for preparation thereof. The compounds of the present invention can target DNA vaccines to antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs), via mannose receptors expressed on the cell surface of APCs. The cationic amphiphiles disclosed herein show enhanced cellular and humoral immune response compared to their mannosyl counterparts in genetic immunization in mice. The present invention discloses that immunization with electrostatic complexes (lipoplexes) of DNA vaccines encoding melanoma antigens (gp100 and tyrosinase) and liposome of the presently described novel lysinylated cationic amphiphiles with mannose-mimicking shikimoyl head-groups provides long-lasting (100 days post melanoma tumor challenge) protective immunity in all immunized mice. Cationic amphiphiles with mannose-mimicking shikimoyl head-groups described in the present invention are likely to find future applications in the field of genetic immunization.

The present invention relates to the mannose-receptor selective lysinylated cationic amphiphile and a process for preparation thereof. The compounds of the present invention can target DNA vaccines to antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs), via mannose receptors expressed on the cell surface of APCs. The cationic amphiphiles disclosed herein show enhanced cellular and humoral immune response compared to their mannosyl counterparts in genetic immunization in mice. The present invention discloses that immunization with electrostatic complexes (lipoplexes) of DNA vaccines encoding melanoma antigens (gp100 and tyrosinase) and liposome of the presently described novel lysinylated cationic amphiphiles with mannose-mimicking shikimoyl head-groups provides long-lasting (100 days post melanoma tumor challenge) protective immunity in all immunized mice. Cationic amphiphiles with mannose-mimicking shikimoyl head-groups described in the present invention are likely to find future applications in the field of genetic immunization.

A bactericidal or bacteriostatic composition comprising an isomer mixture of monosaccharide alkyl monoethers or monoacetals, its use in the treatment or prevention of Gram-positive bacterial infections, its use as a hygiene or dermatological product for external use and a method for disinfecting surfaces.

A bactericidal or bacteriostatic composition comprising an isomer mixture of monosaccharide alkyl monoethers or monoacetals, its use in the treatment or prevention of Gram-positive bacterial infections, its use as a hygiene or dermatological product for external use and a method for disinfecting surfaces.

The present invention relates to a 3′-ketoglycoside compound defined by formula (I) and its use for controlled release of alcohols, in particular alcohols showing an insect repellent effect. It relates also to a process for preparing the 3′-ketoglycoside compound of formula (I). It further relates to a composition comprising a 3′-ketoglycoside compound of formula (I). It relates also to the use of a 3′-ketoglycoside compound of formula (I) for the controlled release of alcohols. It related also to a method of use of such composition.

The invention relates to the cosmetic use of at least one compounds according to the following formula (I), as an anti-dandruff agent or for preventing and/or treating scalp dandruff: where “sugar” denotes a monosaccharide residue chosen from rhamnose, xylose, fucose, mannose, lyxose, and arabinose; where R, substituting the anomeric oxygen in the sugar (represented by “O” in formula (I)), denotes a radical comprising 6 to 38 carbon atoms chosen from: —a linear or branched, saturated alkyl radical; —a linear or branched, alkenyl radical; said linear or branched saturated alkyl radical being optionally substituted by at least one OH and/or NH2 function; —if “sugar” denotes a mannose residue, R denotes a linear C6-C38 alkyl radical, substituted by at least one OH function or an NH2 function; and the salts and solvates and/or optical isomers thereof, alone or in a mixture, particularly racemic forms. The invention also relates to compounds according to formula (I), and cosmetic compositions containing same. ##STR00001##

The invention relates to the cosmetic use of at least one compounds according to the following formula (I), as an anti-dandruff agent or for preventing and/or treating scalp dandruff: where “sugar” denotes a monosaccharide residue chosen from rhamnose, xylose, fucose, mannose, lyxose, and arabinose; where R, substituting the anomeric oxygen in the sugar (represented by “O” in formula (I)), denotes a radical comprising 6 to 38 carbon atoms chosen from: —a linear or branched, saturated alkyl radical; —a linear or branched, alkenyl radical; said linear or branched saturated alkyl radical being optionally substituted by at least one OH and/or NH2 function; —if “sugar” denotes a mannose residue, R denotes a linear C6-C38 alkyl radical, substituted by at least one OH function or an NH2 function; and the salts and solvates and/or optical isomers thereof, alone or in a mixture, particularly racemic forms. The invention also relates to compounds according to formula (I), and cosmetic compositions containing same. ##STR00001##

The present invention relates to processes for the preparation of ertugliflozni. The present invention also provides compounds of Formula (III), Formula (IV), and Formula (VII), processes for their preparation, and their use for the preparation of ertugliflozin. The processes of the present invention involve protecting the ertugliflozin intermediate compound with a suitable protecting group which provides ertugliflozin having high purity and yield.

The present invention relates to processes for the preparation of ertugliflozni. The present invention also provides compounds of Formula (III), Formula (IV), and Formula (VII), processes for their preparation, and their use for the preparation of ertugliflozin. The processes of the present invention involve protecting the ertugliflozin intermediate compound with a suitable protecting group which provides ertugliflozin having high purity and yield.

The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. In one embodiment, the present invention provides a method of treating an immune and inflammatory disorders disorder by administering a composition comprising a therapeutically effective dosage of an ascaroside compound, or a mixture of ascaroside compounds, or a mixture containing at least one ascaroside.